

INDEX

A

- Abscess: renal, after renal artery embolization, Nov. 49-50
- Acromegaly, Feb. 11-13
 - categorization of tumor in, Feb. 12
 - etiology, Feb. 13
 - pituitary lesion in, immunocytochemistry of, Feb. 13
 - surgery results, Feb. 12
- Adenocarcinoma: cervix, uterine artery infusion in, Dec. 28
- Adenoma
 - abnormal events in pancreas leading to, Sept. 25
 - beta cell, Sept. 13
 - pancreatic, solitary, Sept. 18
 - islet cell
 - beta, hyperfunctioning, Sept. 19
 - solitary, Sept. 12
 - solitary, blush of, Sept. 14
 - nonfunctioning, Feb. 15-16
 - null cell, Feb. 15-16
 - pituitary (*see* Pituitary, adenoma)
 - prolactin, Feb. 13-14
 - surgery results, Feb. 14
- Adenomatosis
 - multiple endocrine, Sept. 30-31
 - pancreatic beta cell, Sept. 18-21
- Adrenal
 - hypothalamic-pituitary axis, Feb. 8
 - neuroblastoma (*see* Neuroblastoma, adrenal)
- Age
 - at diagnosis in thyroid carcinoma, Aug. 26
 - medulloblastoma and (*see under* Medulloblastoma)
 - thyroid carcinoma survival by, Aug. 42-43
- Air studies: in medulloblastoma, May 39
- Alkaloids: plant, nephrotoxicity of, Oct. 21-22
- Alkylating agents:
 - nephrotoxicity, Oct. 5-10
- Angiofibroma of nasopharynx, Dec. 45-47
 - diagnosis, Dec. 45-46
 - intra-arterial chemotherapy of, Dec. 46-47
- Angiography
 - cerebellar, in medulloblastoma, May 37-39
 - iliac, of sacral giant cell tumor, Dec. 15
 - of melanoma, Dec. 31-33
- Anthracyclines: nephrotoxicity, Oct. 18
- Antibiotics: antitumor,
 - nephrotoxicity, Oct. 18-21
- Antibodies: insulin,
 - measurement, Sept. 9-10
- Antidiuretic hormone, Feb. 6
- Antigens: sarcoma-associated, in urine, evaluation, Mar. 9
- Antimetabolites: nephrotoxicity, Oct. 13-18
- Antineoplastic drugs
 - for intra-arterial infusion, Nov. 6-7
 - nephrotoxicity of, Oct. 3-32
- Antitumor antibiotics:
 - nephrotoxicity, Oct. 18-21
- Apudoma, Nov. 42-44
 - hepatic artery infusion in complications, Nov. 43
 - results, Nov. 43
- Arteries
 - auricular, Dec. 39
 - carotid, external, Dec. 39
 - facial, Dec. 39
 - gastroduodenal, occlusion in hepatic artery infusion chemotherapy, Nov. 14
 - gluteal, occlusion for infusion in carcinoma of cervix, Dec. 21
 - hepatic (*see* Hepatic artery)
 - iliac, infusion by, Nov. 13

INDEX

A

- Abscess: renal, after renal artery embolization, Nov. 49-50
- Acromegaly, Feb. 11-13
 - categorization of tumor in, Feb. 12
 - etiology, Feb. 13
 - pituitary lesion in, immunocytochemistry of, Feb. 13
 - surgery results, Feb. 12
- Adenocarcinoma: cervix, uterine artery infusion in, Dec. 28
- Adenoma
 - abnormal events in pancreas leading to, Sept. 25
 - beta cell, Sept. 13
 - pancreatic, solitary, Sept. 18
 - islet cell
 - beta, hyperfunctioning, Sept. 19
 - solitary, Sept. 12
 - solitary, blush of, Sept. 14
 - nonfunctioning, Feb. 15-16
 - null cell, Feb. 15-16
 - pituitary (*see* Pituitary, adenoma)
 - prolactin, Feb. 13-14
 - surgery results, Feb. 14
- Adenomatosis
 - multiple endocrine, Sept. 30-31
 - pancreatic beta cell, Sept. 18-21
- Adrenal
 - hypothalamic-pituitary axis, Feb. 8
 - neuroblastoma (*see* Neuroblastoma, adrenal)
- Age
 - at diagnosis in thyroid carcinoma, Aug. 26
 - medulloblastoma and (*see* under Medulloblastoma)
 - thyroid carcinoma survival by, Aug. 42-43
- Air studies: in medulloblastoma, May 39
- Alkaloids: plant, nephrotoxicity of, Oct. 21-22
- Alkylating agents:
 - nephrotoxicity, Oct. 5-10
- Angiofibroma of nasopharynx, Dec. 45-47
 - diagnosis, Dec. 45-46
 - intra-arterial chemotherapy of, Dec. 46-47
- Angiography
 - cerebellar, in medulloblastoma, May 37-39
 - iliac, of sacral giant cell tumor, Dec. 15
 - of melanoma, Dec. 31-33
- Anthracyclines: nephrotoxicity, Oct. 18
- Antibiotics: antitumor,
 - nephrotoxicity, Oct. 18-21
- Antibodies: insulin,
 - measurement, Sept. 9-10
- Antidiuretic hormone, Feb. 6
- Antigens: sarcoma-associated, in urine, evaluation, Mar. 9
- Antimetabolites: nephrotoxicity, Oct. 13-18
- Antineoplastic drugs
 - for intra-arterial infusion, Nov. 6-7
 - nephrotoxicity of, Oct. 3-32
- Antitumor antibiotics:
 - nephrotoxicity, Oct. 18-21
- Apudoma, Nov. 42-44
 - hepatic artery infusion in complications, Nov. 43
 - results, Nov. 43
- Arteries
 - auricular, Dec. 39
 - carotid, external, Dec. 39
 - facial, Dec. 39
 - gastroduodenal, occlusion in hepatic artery infusion chemotherapy, Nov. 14
 - gluteal, occlusion for infusion in carcinoma of cervix, Dec. 21
 - hepatic (*see* Hepatic artery)
 - iliac, infusion by, Nov. 13

intra-arterial (*see* Intra-arterial)
 lingual, Dec. 39
 maxillary, Dec. 39
 occipital, Dec. 39
 pharyngeal, Dec. 39
 renal (*see* Kidney, carcinoma, renal artery embolization)
 stenotic segment, catheterization through, Nov. 16
 temporal, Dec. 39
 thyroidal, Dec. 39
 uterine, in infusion of adenocarcinoma of cervix, Dec. 28
 Arteriography: in islet cell adenoma, Sept. 14
 L-Asparaginase: nephrotoxicity, Oct. 16
 Astrocytoma: cerebellar, differential diagnosis, May 37
 Auricular artery, Dec. 39
 5-Azacytidine: nephrotoxicity, Oct. 15

B

Basal cell nevus: and cerebellar medulloblastoma, May 8-9
 BCNU: with cisplatin in brain tumors, Dec. 38
 Beta cell adenoma (*see under* Adenoma)
 adenomatosis, pancreatic, Sept. 18-21
 carcinoma, pancreatic, Sept. 18
 Beta islet cell carcinoma, Sept. 35
 hyperplasia, Sept. 21
 Biologic effectiveness, relative, July 19-20
 expression of energy exchange, July 17-19
 Biopsy aspiration cytology, in thyroid carcinoma, Aug. 23-25
 bone core, in hairy cell leukemia, Jan. 8
 in soft tissue sarcoma of extremity, Mar. 13-14

interpretation, Mar. 14-15
 Bladder carcinoma (*see below*)
 in rhabdomyosarcoma, Apr. 40
 tumors, and rhabdomyosarcoma, Apr. 36-38
 Bladder carcinoma, Dec. 17-26
 cisplatin in, Dec. 22-24
 chemotherapy, details concerning, Dec. 23
 complications, Dec. 23-24
 cisplatin in, intra-arterial and systemic, Dec. 25-26
 chemotherapy, details concerning, Dec. 25
 complications, Dec. 25-26
 results, Dec. 25
 cisplatin in, results, Dec. 23
 evaluation methods, Dec. 19
 5-fluorouracil in, Dec. 24-25
 chemotherapy, details concerning, Dec. 24
 complications, Dec. 25
 results, Dec. 24-25
 heparinization in, systemic, Dec. 22
 intra-arterial chemotherapy of, Dec. 19-26
 isotopic monitoring of flow distribution, Dec. 22
 technical considerations, Dec. 19-22
 radiography of, Dec. 19
 staging system, Dec. 18
 Bleeding (*see* Hemorrhage)
 Blood volume: homeostatic control, Feb. 7
 Bone core biopsy, in hairy cell leukemia, Jan. 8
 eosinophilic granuloma (*see* Eosinophilic granuloma of bone)
 marrow, in hairy cell leukemia, Jan. 7-11
 metastases from kidney carcinoma, embolization of, Nov. 53
 sarcoma, staging system, Mar. 18
 scans in medulloblastoma, May 40

Brain

- scan in medulloblastoma, May 37
- tumors, Dec. 33-39
 - cisplatin in, Dec. 36-38
 - cisplatin plus BCNU in, Dec. 38
 - etoposide-VP16 in, Dec. 38
 - intra-arterial chemotherapy of, Dec. 34-39
 - intra-arterial chemotherapy of, results, Dec. 36-39
 - intra-arterial chemotherapy of, technical considerations, Dec. 36
 - metastatic, cisplatin in, Dec. 37-38

- Breast carcinoma, Nov. 40-42
 - hepatic artery embolization in, Nov. 41-42
 - hepatic artery infusion in, Nov. 40-41
 - intra-arterial therapy in, Nov. 42
 - liver metastases from, Nov. 40
 - hepatic artery infusion in, Nov. 42

C

- Calcium: infusion test, Sept. 12-13

Cancer

CNS

- basal cell nevoid associated with, May 8-9
- conditions associated with, May 6-7
- familial aggregation, May 7
- hereditary factors in, May 7
- incidence, May 9-11
- embolization in (*see* Embolization)
- infarction in, Nov. 4-62, Dec. 4-55
- infusion in (*see* Infusion)
- isolation-perfusion in, Nov. 17-18
- late, after radiation, June 11
- liver (*see* Liver, cancer)
- radiation in (*see* Radiation, in cancer)

radiotherapy (*see* Radiotherapy, cancer)

three most common, in adults and children, May 6

volume doubling times, July 21

- Carcinoid: of lung, liver
 - metastases from, hepatic artery embolization in, Nov. 44

Carcinoma

- bladder (*see* Bladder carcinoma)
- breast (*see* Breast, carcinoma)
- cervix (*see* Cervix, carcinoma)
- colon (*see* Colon, carcinoma)
- hepatocellular, Nov. 35-36
- islet cell, beta, Sept. 35
- kidney (*see* Kidney, carcinoma)
- pancreas, beta cell, Sept. 18
- rectosigmoid, hemorrhage in, embolization of, Nov. 23
- rectum, Nov. 36-40
 - hepatic artery infusion in, adjuvant, Nov. 37-38
 - thyroid (*see* Thyroid carcinoma)

Care: city and health, in thyroid carcinoma study, Aug. 10

Carotid artery: external, Dec. 39

Catheter (*see under* Infusion)

Catheterization

- with infusion of left gastric to right gastric collateral, Nov. 28
- selective, for infusion, Nov. 7-8
- through stenotic segment of artery, Nov. 16

Cell(s)

- basal cell nevoid and cerebellar medulloblastoma, May 8-9
- beta (*see* Beta cell)
- cycle, functional model of, July 33
- epidermal (*see under* Epidermal)
- giant (*see* Giant cell)
- hairy (*see* Hairy cells)
- HeLa, irradiated, survival curve for, July 34
- irradiated (*see* Radiation, cell)
- islet (*see* Islet cell)
- kinetic concepts in radiation, July 20-28
- kinetic parameters in humans, July 23

markers in hairy cell leukemia,
 Jan. 17
 of medulloblastoma,
 cytogenesis, May 11-12
 mononuclear, in spleen, Jan. 11
 null cell adenoma, Feb. 15-16
 population changes after
 radiation, graphic
 representation, July 24
 responses to radiation,
 diagrammatic
 representation, July 17
 T cell variant in hairy cell
 leukemia, Jan. 20-21
 tendosynovial, tumors, Mar.
 20-21
 unirradiated cell population
 kinetics, July 20-22
 Central nervous system (*see* CNS)
 Cerebellar
 angiography in
 medulloblastoma, May
 37-39
 astrocytoma, differential
 diagnosis, May 37
 medulloblastoma (*see*
 Medulloblastoma,
 cerebellar)
 signs in medulloblastoma, May
 21
 syndrome in medulloblastoma,
 May 23
 Cerebrospinal fluid
 cytology in medulloblastoma,
 May 40
 polyamine putrescine levels,
 May 40
 Cervical: thoracocervical
 neuroblastoma, in infant,
 Apr. 31
 Cervix: adenocarcinoma, uterine
 artery infusion in, Dec. 28
 Cervix, carcinoma, Dec. 26-30
 intra-arterial chemotherapy in,
 Dec. 27-30
 chemotherapy, details
 concerning, Dec. 28
 complications, Dec. 30
 results, Dec. 29-30
 stage IIIB carcinoma, Dec. 29
 intra-arterial chemotherapy
 and radiotherapy of
 complications, Dec. 30

 results, Dec. 30
 stage III, gluteal artery
 occlusion for infusion of,
 Dec. 21
 staging system, Dec. 26
 Chemoembolization, Nov. 20-21
 Chemotherapy
 adjuvant, in extremity soft
 tissue sarcoma, Mar. 31-33
 trials, Mar. 34
 combination, in extremity soft
 tissue sarcoma, Mar. 28-31
 infusion (*see* Infusion)
 in insulinoma, metastatic, Sept.
 36-37
 intra-arterial (*see* Intra-
 arterial, chemotherapy)
 medulloblastoma (*see*
 Medulloblastoma,
 chemotherapy)
 of neuroblastoma, adrenal, Apr.
 22
 of renal carcinoma, Nov. 47
 of soft tissue sarcoma of
 extremity, Mar. 25
 systemic, Nov. 5
 toxicity of, June 23-24
 Children
 cancer in, three most common,
 May 6
 infant
 neuroblastoma, adrenal, Apr.
 20
 neuroblastoma, adrenal, with
 hepatic metastases, Apr. 19
 neuroblastoma, adrenal, CT
 of, Apr. 22
 neuroblastoma infiltrating
 kidney in, Apr. 25
 neuroblastoma,
 thoracocervical, Apr. 31
 medulloblastoma
 radiotherapy, survival curves
 after, May 16
 survival status after
 radiotherapy, June 19
 Wilm's tumor
 lung metastases in 1-year-
 old, Apr. 17
 2-year-old, Apr. 14
 Children's Cancer Study Group
 and Radiation Therapy
 Oncology Group Joint

Children's Cancer Study Group

(*cont.*)

Study, June 21

Chloroethyl nitrosoureas:

nonglycosylated,
nephrotoxicity, Oct. 12-13

Circulation: collateral, in liver
cancer infusion, Nov.
27-29

Cisplatin

in bladder carcinoma (*see*
Bladder carcinoma,
cisplatin in)

in brain tumors, Dec. 36-38

in breast carcinoma, via
hepatic artery infusion,
Nov. 40-41

infusion, femoral arteriography
before, Dec. 9

kidney after, Oct. 6, 7, 8

in metastases of brain tumors,
Dec. 37-38

nephrotoxicity of, Oct. 5-9
toxicities, Dec. 38-39

CNS

cancer (*see* Cancer, CNS)
tumors, malignant, conditions
associated with, May 6-7

Coil: stainless steel, for
embolization, Nov. 20

Colon

carcinoma, Nov. 36-40
embolization of hepatic
metastases from, Nov. 31

hepatic artery infusion in,
adjuvant, Nov. 37-38

metastases to pelvis, Nov. 39-40

Computed (*see* Tomography,
computed)

Concepts (*see* Radiation, concepts)

C-peptide: measurement of, Sept.
9-10

CSF (*see* Cerebrospinal fluid)

CT (*see* Tomography, computed)

Cushing's disease, Feb. 14-15
surgery results, Feb. 15

Cyclosporin A: nephrotoxicity,
Oct. 22-23

Cystitis: bleeding radiation,
embolization of, Nov. 24

Cytology: aspiration biopsy, in
thyroid carcinoma, Aug.
23-25

Cytoplasm: of hairy cells, Jan. 6

D

Dose (*see* Radiation, dose)

Drug(s)

antineoplastic (*see*
Antineoplastic drugs)
dosage adjustment for renal
insufficiency, Oct. 4-5
immunosuppressive,
nephrotoxicity of, Oct.
3-32

Duodenal ulcer: embolization in,
Nov. 22

Dysmyelopoiesis: in hairy cell
leukemia, Jan. 26-27

E

Electron microscopy

in medulloblastoma, May 14
transmission, of hairy cells,
Jan. 5

Embolization, Nov. 18-21

of bone metastases from kidney
carcinoma, Nov. 53

chemoembolization, Nov. 20-21
coil for, stainless steel, Nov. 20
Gelfoam for, Nov. 19

of giant cell tumors (*see* Giant
cell tumors, embolization)

of head and neck tumors (*see*
Head and neck tumors,
embolization of)

of hemorrhage

in radiation cystitis, Nov. 24
from rectal pouch, Nov. 23

hepatic artery (*see* Hepatic
artery, embolization)

of hepatic metastases from
colon carcinoma, Nov. 31

of hypernephroma in solitary
kidney, Nov. 52

Ivalon for, Nov. 19

in lung metastases, response to,
Nov. 48

renal artery (*see* Kidney,
carcinoma, renal artery
embolization)

of ulcer, duodenal, Nov. 22

Endocrine

(*See also* Multiple endocrine
neoplasia syndrome)

functions after radiation, June
10

status after medulloblastoma treatment, June 33-43

Energy exchange
 between incident radiation and tissue, July 10
 biologic expression of, July 17-19
 interaction of radiation with tissue, July 14

Eosinophilic granuloma of bone, Dec. 15-26
 methylprednisolone in, intralesional, Dec. 16-17
 results, Dec. 16
 technique, Dec. 16
 tibia, left, Dec. 17

Ependymoma: differential diagnosis, May 36

Epidermal
 basal cell monolayer, July 25
 cell renewal system, July 22

Etoposide-VP16: in brain tumors, Dec. 38

Extracellular fluid: homeostatic control of, Feb. 6

Extrasosseous tumors, Mar. 21

Extremity hemihypertrophy: after Wilm's tumor surgery, Apr. 7

Extremity: in rhabdomyosarcoma, Apr. 38-39, 40-41

Extremity soft tissue sarcoma, Mar. 3-41
 anatomical considerations, Mar. 11
 anatomical locations, Mar. 18
 benign, Mar. 12
 biopsy in, Mar. 13-14
 interpretation, Mar. 14-15
 chemotherapy, Mar. 25
 adjuvant, Mar. 31-33
 adjuvant, trials, Mar. 34
 with surgery, Mar. 28-31
 classification, Mar. 6
 pathologic, Mar. 16-17
 clinical presentation, Mar. 12-21
 etiology, Mar. 5-7
 evaluation, clinical, Mar. 15
 "fish flesh" consistency of, Mar. 4
 frequency, Mar. 18
 growth characteristics, local, Mar. 10-12

histogenic theory of, Mar. 6
 histogenic variants, frequency, Mar. 20
 histologic identification and grade, Mar. 19
 histologic types, frequency and characteristics of, Mar. 17-21
 historical aspects, Mar. 3-5
 immunology, Mar. 8-9
 markers, Mar. 9-10
 metastatic patterns, Mar. 12
 multidisciplinary therapy, Mar. 25-31
 multimodality limb salvage program in, Mar. 31
 pathologic observations, Mar. 10-11
 radiotherapy of, Mar. 24-25
 with surgery, Mar. 25-28
 with surgery, trials, Mar. 27
 "shrinking fields" concept in, Mar. 30
 staging, Mar. 16
 staging system, Mar. 18
 statistics, Mar. 5-7
 surgery of, Mar. 22-24
 with chemotherapy, combination, Mar. 28-31
 with radiotherapy, Mar. 25-28
 with radiotherapy, trials, Mar. 27
 results, Mar. 23
 treatment, Mar. 21-35
 of metastases, Mar. 33-35
 trials, multimodality, Mar. 32

F

Facial artery, Dec. 39

Femoral arteriography: before cisplatin infusion, Dec. 9

Fibrosarcoma, Mar. 17-18

Fibrous histiocytoma: malignant, Mar. 19-20

"Fish flesh" consistency: of soft tissue sarcoma, Mar. 4

Fluid: extracellular, homeostatic control of, Feb. 6

5-Fluorouracil (*see* Bladder carcinoma, 5-fluorouracil in)

Fossa: posterior, tumor,
symptoms and signs of,
May 19-21

G

Gait: unsteadiness in
medulloblastoma, May 23
Gas: after renal artery
embolization, Nov. 49-50
Gastroduodenal artery: occlusion
in hepatic arterial infusion
chemotherapy, Nov. 14
Gastrointestinal hemorrhage:
infusion for control, Nov.
22-23
Gelfoam: for embolization, Nov.
19
Genitourinary hemorrhage:
infusion for control, Nov.
23
Giant cell tumors, Dec. 12-15
embolization of, Dec. 13-15
results, Dec. 14-15
technique, Dec. 13-14
sacral, iliac angiography of,
Dec. 15
Glioblastoma multiforme: of
parietal lobe, Dec. 37
Glucose
levels after fasting and calcium
stimulation, Sept. 12
monitoring, intraoperative
plasma, Sept. 34-35
Gluteal artery: occlusion for
infusion in carcinoma of
cervix, Dec. 21
Goiter, Aug. 4
Gonadal-hypothalamic-pituitary
axis
in female, Feb. 9
in male, Feb. 8
Gonadotropin: chorionic, in
hyperinsulinism, Sept. 10
Granuloma (*see* Eosinophilic
granuloma)
Growth
hormone-hypothalamic-
pituitary-growth axis,
Feb. 9
after medulloblastoma
treatment, June 31-33
problems after radiation,
June 9

H

Hair loss: after radiation, June 9
Hairy cell(s)
cytoplasm of, Jan. 6
infiltrates of, portal and
sinusoidal, Jan. 13
leukemia (*see below*)
microscopy of
electron, transmission, Jan. 5
light, Jan. 4
Hairy cell leukemia, Jan. 3-33
bone core biopsy in, Jan. 8
cell of origin in, Jan. 17-21
cellular markers in, Jan. 17
complications, Jan. 27
infectious, Jan. 24
cytochemistry, Jan. 4-7
cytology, Jan. 4-7
diagnosis, differential, Jan. 9
dysmyelopoiesis in, Jan. 26-27
familial, Jan. 27-28
future directions, Jan. 33-34
host immunity alteration in,
Jan. 21-23
immune disorders and, Jan. 26
infection in, Jan. 23-26
commonly identified
organisms, Jan. 24
mycobacterial, Jan. 25
liver in, Jan. 13-14
marrow in, Jan. 7-11
presentation
clinical, Jan. 14-17
laboratory values at, Jan. 16
physical findings at, Jan. 15
presenting symptoms, Jan. 15
spleen in, Jan. 11-13
T cell variant in, Jan. 20-21
tissue involvement in, Jan.
7-14
treatment, Jan. 28-33
response, Jan. 33
Head
and neck tumors (*see below*)
rhabdomyosarcoma, Apr. 35-36
nonparameningeal, Apr. 40
Head and neck tumors, Dec.
39-47
embolization of, Dec. 42-45
complications, Dec. 44-45
technical considerations, Dec.
43-44

- intra-arterial chemotherapy of,
 Dec. 40-42
 complications, Dec. 42
 occlusion for infusion, Dec.
 41-42
 results, Dec. 42
 technique, Dec. 41-42
 vascular supply, Dec. 39-40
 Headaches: in medulloblastoma,
 May 22-23
 Hearing loss: sensory, after
 radiation, June 10
 HeLa cells: irradiated, survival
 curve, July 34
 Hemihypertrophy: of extremity
 after Wilms' tumor
 surgery, Apr. 7
 Hemolytic-uremic syndrome:
 mitomycin C-induced,
 kidney after, Oct. 19, 20,
 21
 Hemorrhage
 control, infusion in, Nov. 21-23
 gastrointestinal hemorrhage,
 Nov. 22-23
 genitourinary hemorrhage,
 Nov. 23
 of radiation cystitis,
 embolization of, Nov. 24
 from rectal pouch, embolization
 in, Nov. 23
 Heparinization: systemic, and
 bladder carcinoma, Dec. 22
 Hepatic (*See also* Liver)
 Hepatic artery
 embolization, Nov. 30-35
 in breast carcinoma, Nov.
 41-42
 complications, Nov. 33
 contraindications, Nov.
 33-34
 indications, Nov. 32
 with infusion in hepatoma,
 Nov. 37
 for liver metastases from
 lung carcinoid, Nov. 44
 side effects, Nov. 32-33
 technique, Nov. 30-32
 infusion, Nov. 30
 adjuvant, in colorectal
 carcinoma, Nov. 37-38
 in apudoma, complications,
 Nov. 43
 in apudoma, results, Nov. 43
 in breast carcinoma, Nov.
 40-41
 with embolization in
 hepatoma, Nov. 37
 gastroduodenal artery
 occlusion in, Nov. 14
 for liver metastases from
 breast carcinoma, Nov. 42
 occlusion, portal vein infusion
 after, Nov. 34-35
 redistribution for hepatic
 infusion chemotherapy,
 Nov. 12
 Hepatocellular carcinoma, Nov.
 35-36
 Hepatoma: hepatic artery
 infusion and embolization
 in, Nov. 37
 Hereditary factors
 in cerebellar medulloblastoma,
 May 8-9
 in CNS cancer, May 7
 Histiocytoma: malignant fibrous,
 Mar. 19-20
 Homeostatic control
 of blood volume, Feb. 7
 of extracellular fluid, Feb. 6
 Hormone(s)
 antidiuretic, Feb. 6
 growth hormone-hypothalamic-
 pituitary axis, Feb. 9
 -producing metastases to liver,
 Nov. 42-43
 therapy of renal carcinoma,
 Nov. 46-47
 Host immunity: alteration in
 hairy cell leukemia, Jan.
 21-23
 Hydrocephalus, irreversible, in
 medulloblastoma, May 28
 incidence and prognosis in,
 May 29
 surgery, May 29
 Hydroxyurea: nephrotoxicity, Oct.
 16
 Hyperinsulinemic hypoglycemia:
 in newborn, Sept. 32-34
 Hyperinsulinism, Sept. 4-43
 clinical presentation, Sept. 5
 endogenous, Sept. 18
 hyperplasia in, Sept. 22
 laboratory features, Sept. 7-13

Hyperinsulinism (*cont.*)
 pathology, Sept. 17-28
 pathophysiology, Sept. 17-28
 pharmacologic control, Sept.
 35-36
 preoperative localization, Sept.
 13-17
 stimulation tests in, Sept.
 11-13
 suppression tests in, Sept.
 10-11
 surgical complications, Sept. 55
 surgical management of, Sept.
 31-35
 Hypernephroma: in solitary
 kidney, embolization of,
 Nov. 52
 Hyperplasia
 beta islet cell, Sept. 21
 in hyperinsulinism, Sept. 22
 Hypertension: after renal artery
 embolization of carcinoma,
 Nov. 49
 Hypoglycemia
 diagnosis, differential, Sept.
 5-7
 fasting, Sept. 6-7
 hyperinsulinemic, in newborn,
 Sept. 32-34
 in hyperinsulinism, Sept. 7-8
 postabsorptive, Sept. 5-6
 Hypothalamic
 -pituitary-adrenal axis, Feb. 8
 -pituitary-gonadal axis
 in female, Feb. 9
 in male, Feb. 8
 -pituitary-growth hormone axis,
 Feb. 9
 -pituitary-prolactin axis, Feb.
 10
 -pituitary-thyroid axis, Feb. 7

I

Iliac
 angiography, of sacral giant
 cell tumor, Dec. 15
 artery, infusion by, Nov. 13
 Imaging (*see* Scan)
 Immune disorders: and hairy cell
 leukemia, Jan. 26
 Immunity: host, alteration in
 hairy cell leukemia, Jan.
 21-23

Immunology: and extremity soft
 tissue sarcoma, Mar. 8-9
 Immunosuppressive drugs:
 nephrotoxicity of, Oct.
 3-32
 Immunotherapy: of renal
 carcinoma, Nov. 47
 Infant (*see* Children, infant)
 Infarction: in cancer, Nov. 4-62,
 Dec. 4-55
 Infusion, Nov. 4-62, Dec. 4-55
 administration
 choice, Nov. 10-11
 frequency, Nov. 10-11
 in cancer, Dec. 4-55
 catheter
 displacement of, Nov. 15
 fixation, Nov. 8
 position monitoring, Nov. 9
 catheterization for
 left gastric to right gastric
 collateral, Nov. 28
 selective, Nov. 7-8
 chemotherapy delivery, Nov.
 9-10
 complications of, Nov.
 13-17
 flow, pulsatile vs. nonpulsatile,
 Nov. 12-13
 in hemorrhage control, Nov.
 21-23
 gastrointestinal, Nov.
 22-23
 genitourinary, Nov. 23
 hepatic artery (*see* Hepatic
 artery)
 hepatic, hepatic arterial
 redistribution for, Nov. 12
 by iliac artery, Nov. 13
 infection complicating, Nov.
 16-17
 intra-arterial (*see* Intra-
 arterial, infusion)
 in liver cancer (*see* Liver,
 cancer, infusion in)
 occlusion-infusion, Nov. 17
 occlusion for, selective, Nov.
 11-12
 portal, Nov. 8-9
 portal vein, after hepatic artery
 occlusion, Nov. 34-35
 redistribution of vascular
 supply, Nov. 11
 techniques, Nov. 7-17

thrombogenic environment for,
Nov. 8
vascular trauma complicating,
Nov. 13-15

Insulin
antibodies, measurement of,
Sept. 9-10
after fasting and calcium
stimulation, Sept. 12
immunoreactive, Sept. 8-9

Insulinoma
immunocytochemical findings
in, Sept. 27
metastatic, chemotherapy, Sept.
36-37

Intellectual
development by age, and
medulloblastoma
treatment, June 40
status after medulloblastoma
treatment, June 39-41

**International Society of Pediatric
Oncology Study**, June 21

**Intestinal hemorrhage: infusion
for control**, Nov. 22-23

**Intra-arterial
chemotherapy**
of angiofibroma of
nasopharynx, Dec. 46-47
of bladder carcinoma (*see*
Bladder carcinoma, intra-
arterial chemotherapy of)
in brain tumors (*see* Brain,
tumors, intra-arterial
chemotherapy of)
of cervix, carcinoma (*see*
Cervix, carcinoma, intra-
arterial chemotherapy in)
of head and neck tumors (*see*
Head and neck tumors,
intra-arterial
chemotherapy of)
in melanoma (*see* Melanoma,
intra-arterial
chemotherapy of)
of osteosarcoma (*see*
Osteosarcoma, intra-
arterial chemotherapy of)
infusion, Nov. 5-17
antineoplastic agents for,
Nov. 6-7
cytotoxic agents delivered by,
Nov. 6
rationale, Nov. 5-7

**Intracranial pressure: in
medulloblastoma**, May
19-20

Irradiation (*see* Radiation)

Ischium: osteogenic sarcoma of,
Nov. 13

Islet cell
adenoma (*see* Adenoma, islet
cell)
carcinoma, beta, Sept. 35
hyperplasia, beta, Sept. 21

Isodose
curves, radiation, historical
review, June 13
distribution, June 7

Isoeffect (*see* Radiation, isoeffect)

Isolation-perfusion: in cancer,
Nov. 17-18

**Isotopic monitoring: of flow
distribution in intra-
arterial chemotherapy**,
Dec. 22

**Italian Child's Neuro-oncology
Group Study**, June 22

Ivalon: for embolization, Nov. 19

K

Kidney
abscess after renal artery
embolization, Nov. 49-50
carcinoma, Nov. 45-52
bone metastases from,
embolization of, Nov. 53
chemotherapy, Nov. 47
hormonal therapy, Nov.
46-47
immunotherapy, Nov. 47
liver metastases from, Nov.
54
nephrectomy in, Nov. 45
regression, spontaneous, Nov.
46
renal artery embolization (*see*
below)
skeletal metastases from,
Nov. 53-54
carcinoma, renal artery
embolization, Nov.
47-52
complications, Nov. 49-50
immunologic aspects of, Nov.
50-52
results, Nov. 47-49

Kidney (*cont.*)

- unintentional embolization, Nov. 50
- carcinoma, in solitary kidney, Nov. 52-53
- after cisplatin, Oct. 6, 7, 8
- insufficiency, drug dosage adjustment for, Oct. 4-5
- after mitomycin C-induced hemolytic-uremic syndrome, Oct. 19, 20, 21
- neuroblastoma infiltrating, in infant, Apr. 25
- shutdown after renal embolization, Nov. 49
- solitary carcinoma in, Nov. 52-53
- hypernephroma, embolization of, Nov. 52
- Wilms' tumor, Apr. 9
- stage I, Apr. 6

Kinetic(s)

- parameters in humans, cell, July 23
- unirradiated cell population, July 20-22

L

- L-asparaginase: nephrotoxicity, Oct. 16
- Leptomeningeal tumor deposits: CT of, May 35
- Leukemia (*see* Hairy cell leukemia)
- Light microscopy: of hairy cells, Jan. 4
- Linear energy transfer, July 16
- radiation and, July 16
- Lingual artery, Dec. 39
- Liposarcoma, Mar. 17
- CT of, Mar. 16
- Liver (*See also* Hepatic)
- cancer, infusion in, Nov. 23-36
- anatomical considerations, Nov. 25-27
- collateral circulation for therapy, Nov. 27-29
- criteria for response, Nov. 27-29
- rationale for intra-arterial approach, Nov. 25

- carcinoma, hepatocellular, Nov. 35-36
- in hairy cell leukemia, Jan. 13-14
- metastases
- from adrenal neuroblastoma, Apr. 19
- from breast carcinoma, Nov. 40
- from breast carcinoma, hepatic artery infusion in, Nov. 42
- from colon carcinoma, embolization of, Nov. 31
- hormone-producing, Nov. 42-43
- from kidney carcinoma, Nov. 54
- from lung carcinoid, hepatic artery embolization in, Nov. 44
- nonresectable, Nov. 38-39
- resectable, Nov. 38
- Lobectomy: in thyroid carcinoma, Aug. 5

Lung

- carcinoid, liver metastases
- from, hepatic artery embolization in, Nov. 44
- metastases
- response to embolization and nephrectomy, Nov. 48
- in Wilms' tumor, in infant, Apr. 17

M

- Marrow: in hairy cell leukemia, Jan. 7-11
- Maxillary artery, Dec. 39
- Medulloblastoma, May 4-54
- advanced stage, May 45-46
- air studies in, May 39
- angiography of, cerebellar, May 37-39
- biologic behavior, May 15
- biologic characteristics, May 15-17
- bone scans in, May 40
- brain scan in, May 37
- cells, cytogenesis of, May 11-12
- cerebellar clinical manifestations, May 21-24

- Nov. familial occurrence, May 7-9
 familial occurrence, isolated,
 May 7-8
 hereditary factors in, May
 8-9
 onset mode in, May 21
 symptomatology, May 21
 Nov. cerebellar syndrome in, May 23
 chemotherapy of, May 32, June
 18-24
 current, analysis of, June
 29-30
 with radiotherapy, survival,
 June 20
 toxicity of, June 23-24
 clinical course, May 17-19
 CT of, May 33-36
 with no contrast infusion,
 May 34-35
 follow-up, May 35-36
 with intravenous contrast
 infusion, May 35
 leptomeningeal tumor
 deposits, May 35
 in pattern II, May 44
 in stage I, May 44
 stage III, May 46
 thin hypodense zone in, May
 35
 cystic components of, May 35
 cytogenesis of cells, May 11-12
 cytology, CSF, May 40
 desmoplastic variant, May
 14-15
 diagnosis, May 32-51
 clinical, May 32-33
 differential, May 36-40
 diagnostic studies, May 33-40
 early stage, May 42-43
 epidemiology, May 5-11
 etiology, May 5-6
 extent, and prognosis, May
 27-28
 future for, directions for, June
 43-45
 gait unsteadiness in, May 23
 headaches in, May 22-23
 histologic characteristics, May
 15
 histology, May 31-32
 histopathology, May 12-14
 hydrocephalus in, irreversible,
 May 28
 incidence and prognosis, May
 29
 incidence, May 9-11
 age, May 9
 sex, May 9-10
 invasive, May 47-48
 localized, May 46
 location, May 10-11
 by age, May 11
 incidence by site and age,
 May 10
 prognosis and, May 27-28
 management
 therapeutic, June 4-25
 therapeutic, of primary
 tumor, June 6-24
 manifestations, clinical, May 22
 meningeal invasion by, May 15
 metastatic, May 48
 microscopic histology of, May
 12-13
 microscopic picture of, May 13
 myelography in
 CT-assisted, May 39
 positive, in stage IV, May 47
 in spinal metastases, May 39
 for staging procedures, May
 50-51
 natural history, May 17-32
 neighborhood syndrome in,
 May 24
 neurosurgery in, June 6
 nuclear magnetic resonance
 imaging of, May 37
 papilledema in, May 23
 pathology, May 11-17
 gross, May 12
 pressure syndrome in, May 21
 prognosis
 age in, May 30
 factors influencing, May 27
 sex in, May 30-31
 radiation dose and clinical
 recurrences, May 24
 radiography of, skull, May 40
 radiosensitivity, May 16
 radiotherapy, June 6-18
 basic principles, June 7-8
 with chemotherapy, survival,
 June 20
 in children, survival curves,
 May 16
 dose for, June 14-18

Medulloblastoma (*cont.*)

dose, survival status after, June 18
high-dose, June 16
isodose distribution, June 7
low-dose, June 15-16
method, June 8-9
optimum megavoltage radiotherapeutic techniques, June 15
physiologic development after, June 32
postoperative, May 27
survival after, in children, June 19
survival curves after, May 19
survival rates after, May 27
technique, June 11-14
technique, survival curves in early medulloblastoma and, May 43
technique, survival status after, by age and sex, May 31
at University of Kentucky, June 14
recurrent, retreatment for, June 24-25
results of treatment, June 25-43
functional, June 30-43
performance, June 30-43
shunting procedures in, May 28-29
stage I, May 42-43
Ct of, May 44
stage II, May 43-45
CT of, May 44
stage III, May 45-46
CT of, May 46
with subarachnoid metastases, May 48
stage IV, May 46
staging investigation, proposed neurodiagnostic, May 49
staging procedures, May 48-51
staging system, May 40-48
CT in, May 46-48
subtypes, May 14-15
survival in, May 28, June 25-29
historical review, June 25-26
with modern therapy, June 26-29

past and present, June 26
personal data in, June 30
status by age and sex, May 31
after treatment, psychologist's comments on survivors, June 41-43
tissue culture in, May 16-17
treatment
failure, expected pattern in future, May 26-27
failure pattern, May 24-27
failure, radiation dose and, May 24-25
failure, sites of, May 24
physical development after, June 34-35
physical status after, June 31
vomiting in, May 22
Melanoma, Dec. 31-33
angiography of, Dec. 31-33
intra-arterial chemotherapy of, Dec. 31-32
complications, Dec. 32
response criteria, Dec. 31
results, Dec. 31-32
pelvic, Dec. 33
vulvar, Dec. 32-33
Meninges: invasion by medulloblastoma, May 15
Mental retardation: after radiation, June 10
Metastases
bone, from kidney carcinoma, embolization of, Nov. 53
of brain tumors, cisplatin in, Dec. 37-38
colorectal, to pelvis, Nov. 39-40
extra-CNS, and medulloblastoma treatment failure, May 25-26
in extremity soft tissue sarcoma, Mar. 33-35
of insulinoma, chemotherapy, Sept. 36-37
liver, (*see* Liver, metastases)
lung (*see* Lung, metastases)
of medulloblastoma, May 48
of neuroblastoma, surgery for, Apr. 28
skeletal, from kidney carcinoma, Nov. 53-54
of soft tissue sarcoma of extremity, Mar. 12

spinal (*see* Spinal metastases)
 subarachnoid, in
 medulloblastoma, May 48
 of Wilms' tumor (*see* Wilms'
 tumor, metastases of)
 Methotrexate: nephrotoxicity,
 Oct. 13-15
 Methylprednisolone (*see*
 Eosinophilic granuloma of
 bone, methylprednisolone)
 Microscopic histology: of
 medulloblastoma, May
 12-13
 Microscopic picture: of
 medulloblastoma, May 13
 Microscopy
 electron (*see* Electron
 microscopy)
 light, of hairy cells, Jan. 4
 Microsurgery: transsphenoidal, of
 pituitary adenoma, Feb. 11
 Mithramycin: nephrotoxicity, Oct.
 20-21
 Mitomycin C
 -induced hemolytic-uremic
 syndrome, kidney after,
 Oct. 19, 20, 21
 nephrotoxicity, Oct. 18-20
 Mitotic cycle: position in, and
 survival after radiation,
 July 33-35
 Model(s)
 functional, of cell cycle, July 33
 for radiation survival, July 30
 of tissue response to radiation,
 July 9-14
 Monitoring
 of catheter position for infusion,
 Nov. 9
 isotopic, of flow distribution in
 intra-arterial
 chemotherapy, Dec. 22
 Monolayer: irradiated epidermal
 basal cell, July 25
 Mononuclear cells: in spleen, Jan.
 11
 Mortality: in thyroid carcinoma,
 Aug. 16-19
 Multiple endocrine neoplasia
 syndromes, type I
 pituitary adenoma in, Feb. 17
 sequence of systems, Feb. 17
 Mycobacterial infection: in hairy
 cell leukemia, Jan. 25

Myelography
 CT-assisted, in
 medulloblastoma, May 39
 in medulloblastoma (*see*
 Medulloblastoma,
 myelography)
 of spinal metastases in
 medulloblastoma, May 39
 Myelosuppression: after radiation,
 June 10

N

Nasopharynx (*see* Angiofibroma
 of nasopharynx)
 Nausea: after radiation, June
 9-10
 Neck
 radiotherapy, in thyroid
 carcinoma, Aug. 20
 in rhabdomyosarcoma, Apr.
 35-36
 nonparameningeal, Apr. 40
 tumors (*see* Head and neck
 tumors)
 Neighborhood syndrome: in
 medulloblastoma, May 24
 Nelson's syndrome, Feb. 14-15
 Neoplasia (*see* Tumors)
 Nephrectomy
 with embolization in lung
 metastases, response to,
 Nov. 48
 in renal carcinoma, Nov. 45
 in Wilms' tumor
 with lung metastases, in
 infant, Apr. 17
 stage II, Apr. 8
 Nephroblastoma (*see* Wilms'
 tumor)
 Nephrotoxicity
 alkylating agents, Oct. 5-10
 anthracyclines, Oct. 18
 antimetabolites, Oct. 13-18
 of antineoplastic agents, Oct.
 3-32
 antitumor antibiotics, Oct.
 18-21
 5-azacytidine, Oct. 15
 of cisplatin, Oct. 5-9
 cyclosporin A, Oct. 22-23
 hydroxyurea, Oct. 16
 of immunosuppressive agents,
 Oct. 3-32

Nephrotoxicity (cont.)

- L-asparaginase, Oct. 16
- methotrexate, Oct. 13-15
- mithramycin, Oct. 20-21
- mitomycin C, Oct. 18-20
- nitrosoureas, nonglycosylated
chloroethyl, Oct. 12-13
- nitrosourea, Oct. 10-13
- oxazaphosphorines, Oct. 9-10
- plant alkaloids, Oct. 21-22
- plant derivatives, Oct. 21-23
- purine analogues, Oct. 17-18
- streptozocin, Oct. 10-12
- teniposide, Oct. 22
- Nervous system (see CNS)
- Nesidioblastosis, Sept. 21-26
 - abnormal events in pancreas
leading to, Sept. 25
- Neuroblastoma, Apr. 18-30
 - adrenal
 - CT of, in infant, Apr. 22
 - hepatic metastases from, Apr. 19
 - pyelography in, intravenous,
in infant, Apr. 20
 - CT in, Apr. 21
 - diagnosis, Apr. 18-21
 - future of, Apr. 28-30
 - infiltrating kidney, in infant,
Apr. 25
 - metastases of, surgery for, Apr. 28
 - recommendations for, current,
Apr. 28-30
 - staging, Apr. 21-23
 - staging systems, Apr. 23
 - surgery of, Apr. 23-28
 - delayed primary operation,
Apr. 27
 - second looks, Apr. 27
 - thoracocervical, in infant, Apr. 31
 - treatment, Apr. 5
 - nonoperative, Apr. 28
- Neurologic impairment: localized,
in medulloblastoma, May 20
- Neurosurgery: in
medulloblastoma, June 6
- Neutrons, fast, for radiotherapy,
July 50-53
- incidence of survival after, July 51

- Nevoid: basal cell, and cerebellar
medulloblastoma, May 8-9
- Newborn: hyperinsulinemic
hypoglycemia, treatment,
Sept. 32-34
- Nitrosoureas: nonglycosylated
chloroethyl, nephrotoxicity,
Oct. 12-13
- Nitrosourea: nephrotoxicity of,
Oct. 10-13
- Nuclear magnetic resonance
imaging: of
medulloblastoma, May 37
- Null cell adenoma, Feb. 15-16

O

- Occipital artery, Dec. 39
- Occlusion-infusion, Nov. 17
- Orbit: in rhabdomyosarcoma,
Apr. 40
- Osteogenic sarcoma: of ischium,
Nov. 13
- Osteosarcoma, Dec. 5-12
 - intra-arterial chemotherapy of,
Dec. 6-12
 - chemotherapeutic agents for,
Dec. 7
 - results, Dec. 12
 - technical considerations, Dec. 7-10
 - staging system, Mar. 18
- Otitis: media and externa, after
radiation, June 10
- Oxazaphosphorines:
nephrotoxicity, Oct. 9-10
- Oxygen: in radiation response,
July 36-37

P

- Pain palliation: in bone
metastases, Nov. 53
- Pancreas
 - abnormal events leading to
nesidioblastosis, adenoma,
and islet cell hyperplasia,
Sept. 25
 - adenoma, beta cell, solitary,
Sept. 18
 - adenomatosis, beta cell, Sept. 18-21
 - carcinoma, beta cell, Sept. 18
 - head, venography of, Sept. 16

tumors, mixed endocrine, Sept. 26-28

Papilledema: in medulloblastoma, May 23

Parameningeal:
rhabdomyosarcoma, Apr. 40

Parietal lobe: glioblastoma multiforme of, Dec. 37

Pelvis
colorectal metastases to, Nov. 39-40

melanoma, Dec. 33

Perineal embryonal
rhabdomyosarcoma:
cytology of, Apr. 33

Perineum: in rhabdomyosarcoma, Apr. 40-41

Pharyngeal artery, Dec. 39

Physical status: after therapy of medulloblastoma, June 31

Pituitary
adenoma, Feb. 5-26
classification, Feb. 10
multiple endocrine neoplasia syndromes and, Feb. 17
adenoma, surgery of, Feb. 5-26
microsurgery,
transsphenoidal, Feb. 11
procedure, Feb. 21-26
steps of combined method favored by author, Feb. 20-21
transsphenoidal methods of access, Feb. 18-20

-hypothalamic-adrenal axis, Feb. 8

-hypothalamic-gonadal axis
in female, Feb. 9
in male, Feb. 8

-hypothalamic-growth hormone axis, Feb. 9

-hypothalamic-prolactin axis, Feb. 10

-hypothalamic-thyroid axis, Feb. 7

lesion in acromegaly,
immunocytochemistry of, Feb. 13

tumors, therapy goals, Feb. 10

Plant
alkaloids, nephrotoxicity, Oct. 21-22

derivatives, nephrotoxicity of, Oct. 21-23

Portal infiltrates: of hairy cells, Jan. 13

Portal vein: infusion after hepatic artery occlusion, Nov. 34-35

Postembolization syndrome, Nov. 49

Posterior fossa tumor: symptoms and signs of, May 19-21

Pressure syndrome: in medulloblastoma, May 21

Proinsulin, Sept. 10

Prolactin
adenoma, Feb. 13-14
surgery results, Feb. 14
-hypothalamic-pituitary axis, Feb. 10

Prostate
in rhabdomyosarcoma, Apr. 40
tumors, and
rhabdomyosarcoma, Apr. 36-38

Psychoeducational evaluation:
after medulloblastoma treatment, June 41

Psychologist's comments: on medulloblastoma survivors, June 41-43

Purine analogues: nephrotoxicity, Oct. 17-18

Pyelography, intravenous
in adrenal neuroblastoma, Apr. 20
of Wilms' tumor, stage II, Apr. 8

R

Radiation
(See also Radiography,
Radiotherapy)
action mechanism, July 14-16
in cancer, July 3-36
critical concepts, July 12-13
example, clinical, July 6-8
cell
dose-survival response,
factors modifying, July 32-39
irradiated HeLa cell, survival curve, July 34

Radiation (*cont.*)

- cell population changes
 - produced by, graphic representation, July 24
- cell responses to, diagrammatic representation, July 17
- cell survival, July 27-28
- concepts
 - biologic, July 17-20
 - cell kinetic, July 20-27
 - curves, July 30
 - dependence on radiation dose, July 28-32
- concepts
 - physical aspects, July 14-16
- radiobiologic concepts, July 27-39
- cystitis, hemorrhage of, embolization of, Nov. 24
- dose
 - dependence of cell survival on, July 28-32
 - medulloblastoma failure and, May 24-25
 - in medulloblastoma, and recurrences, May 24
 - in medulloblastoma, and spinal metastases, May 25
 - optimum, June 16-18
 - survival curves according to, June 17
 - time-dose isoeffect and, July 42-45
 - time-dose relationships, and multi-exposure schedules, July 39-45
- effects on normal tissue, June 9-11
- epidermal basal cell monolayer, July 25
- injury, repair of, July 37-39
- interaction of radiation
 - with target molecules, schematic diagram, July 15
 - with tissue, energy exchange in, July 14
- isodose curves, historical review, June 13
- isoeffect
 - empirical, July 41-42
 - plots for skin, July 43
 - time-dose, July 41-42
 - time-dose, dose survival, July 42-45

- linear energy transfer and, July 16
- multi-exposure course of therapy, effect of repair during, July 41
- multi-exposure schedules, and time-dose relationships, July 39-45
- relative biologic effectiveness, July 19-20
- response
 - oxygen in, July 36-37
 - quantification a cell level, July 22-27
- survival
 - cell repair in, July 38
 - models for, July 30
 - position in mitotic cycle, July 33
 - proliferation of cells in, July 36
 - recruitment and, July 33-35
 - redistribution and, July 33-35
 - repopulation, July 35-36
 - time-dose isoeffect and, July 42-45
 - time-dose relationships and multi-exposure schedules, July 39-55
 - tissue response to, model of, July 9-14
- Radiobiologic concepts, July 27-39
- Radiography
 - of bladder carcinoma, Dec. 19
 - skull, in medulloblastoma, May 40
- Radiosensitivity: of
 - medulloblastoma, May 16
- Radiotherapy, July 46-53
 - cancer
 - dose survival parameters, July 32
 - effectiveness for different cancers, July 47
 - of cervical carcinoma (*see* Cervix, carcinoma, intra-arterial chemotherapy and radiotherapy in)
 - of extremity soft tissue sarcoma, Mar. 24-25
 - high-LET, July 50-53
 - machines, evolution of, June 8

in medulloblastoma (*see*
 medulloblastoma,
 radiotherapy)
 of neck in thyroid carcinoma,
 Aug. 20
 neutrons for, fast, July 50-53
 incidence of survival after,
 July 51
 of soft tissue sarcoma of
 extremity with surgery,
 Mar. 25-28
 trials, Mar. 27
 time-dose
 (*See also* dose, time-dose
 above)
 accelerated fractionation,
 July 48-49
 fractionation schedules, July
 47-50
 hyperfractionation, July
 49-50
 standard, July 47-48
 Rectosigmoid carcinoma:
 hemorrhage in,
 embolizations of, Nov. 23
 Rectum
 carcinoma, Nov. 36-40
 hepatic artery infusion in,
 adjuvant, Nov. 37-38
 metastases to pelvis, Nov.
 39-40
 pouch, hemorrhage from,
 embolization in, Nov. 23
 Renal (*see* Kidney)
 Rhabdomyosarcoma, Mar. 21,
 Apr. 30-40, Dec. 43
 bladder in, Apr. 40
 bladder tumors and, Apr.
 36-38
 diagnosis, Apr. 30-32
 extremity in, Apr. 38-39,
 40-41
 future of, Apr. 39-41
 head in, Apr. 35-36
 nonparameningeal, Apr. 40
 Intergroup Study
 findings, Apr. 35-39
 staging system, Apr. 33
 neck in, Apr. 35-36
 nonparameningeal, Apr. 40
 orbit, Apr. 40
 parameningeal, Apr. 40
 perineal embryonal, cytology of,
 Apr. 33

perineum in, Apr. 40-41
 prostate in, Apr. 40
 prostate tumors and, Apr.
 36-38
 recommendations, current, Apr.
 39-41
 relapse, Apr. 39
 staging, Apr. 32-34
 testicular, Apr. 40
 treatment, Apr. 5, 34-35
 trunk in, Apr. 38-39, 40-41
 vulvovaginal, Apr. 40

S

Sacral giant cell tumor: iliac
 angiography of, Dec. 15
 Sarcoma
 -associated antigens in urine,
 evaluation, Mar. 9
 extremity (*see* Extremity soft
 tissue sarcoma)
 fibrosarcoma, Mar. 17-18
 liposarcoma, Mar. 17
 Ct of, Mar. 16
 osteogenic, of ischium, Nov.
 13
 osteosarcoma (*see*
 Osteosarcoma)
 rhabdomyosarcoma (*see*
 Rhabdomyosarcoma)
 soft tissue (*see* Extremity soft
 tissue sarcoma)
 undifferentiated, Mar. 21
 Scanning
 bone, in medulloblastoma, May
 40
 brain, in medulloblastoma, May
 37
 nuclear magnetic resonance, of
 medulloblastoma, May 37
 thyroid, in thyroid carcinoma,
 Aug. 22-23
 results, Aug. 22
 Sex
 incidence in medulloblastoma,
 May 9-10
 in medulloblastoma prognosis,
 May 30-31
 thyroid carcinoma survival by,
 Aug. 43-44
 Shunting procedures: in
 medulloblastoma, May
 28-29

Sinusoidal infiltrates: of hairy cells, Jan. 13
 Skeletal metastases: from kidney carcinoma, Nov. 53-54
 Skin
 isoeffect plots for, radiation, July 43
 reactions to radiation, June 9
 Skull radiography: in medulloblastoma, May 40
 Soft tissue (*see* Extremity soft tissue sarcoma)
 Southwest Oncology Group Study Trial, June 19-21
 Spinal metastases
 in medulloblastoma failure, May 25
 myelography of, May 39
 Spleen
 in hairy cell leukemia, Jan. 11-13
 mononuclear cells, in, Jan. 11
 Stature: after medulloblastoma treatment, June 31-33
 Stenotic segment: of artery, catheterization through, Nov. 16
 Stomach: hemorrhage control, infusion for, Nov. 22-23
 Streptozocin: nephrotoxicity of, Oct. 10-12
 Subarachnoid metastases: in medulloblastoma, May 48
 Subtemporal operation, Feb. 26
 Swiss Pediatric Oncology Group Study Trial, June 21-22
 Synovial: tendosynovial cell tumors, Mar. 20-21

T

T cell variant: in hairy cell leukemia, Jan. 20-21
 Temporal artery, Dec. 39
 Tendosynovial cell tumors, Mar. 20-21
 Teniposide nephrotoxicity, Oct. 22
 Testicular rhabdomyosarcoma, Apr. 40
 Thoracocervical neuroblastoma: in infant, Apr. 31
 Thyroglobulin: in thyroid cancer, Aug. 25

Thyroid
 cancer, thyroglobulin levels in, Aug. 25
 carcinoma (*see below*)
 disorders, possible, prevalence of, Aug. 14-15
 -hypothalamic-pituitary axis, Feb. 7
 nodule, solitary
 palpable, thyroid carcinoma in, frequency, Aug. 18
 surgery for, Aug. 13-14
 scan in thyroid carcinoma, Aug. 22-23
 results, Aug. 22
 screening in healthy women, Aug. 12-13
 Thyroid carcinoma, Aug. 4-49
 abbreviations relating to, Aug. 4-5
 biopsy cytology in, aspiration, Aug. 23-25
 city care in, Aug. 10
 comments on, Aug. 14-44
 definitions relating to, Aug. 4-5
 diagnosis
 age at, Aug. 26
 histopathologic, after surgery of solitary nodule, Aug. 13
 new, 1960-1977, Aug. 11
 distribution by histologic type, Aug. 29, 31
 epidemiologic aspects, Aug. 14-19
 etiology, Aug. 19-25
 evaluation, clinical, Aug. 19-25
 familial disposition, Aug. 19-20
 follicular, Aug. 27
 frequency in palpable solitary nodule, Aug. 18-19
 health care in, Aug. 10
 histopathology, Aug. 25-29
 history in, Aug. 21-22
 incidence, Aug. 16-19
 age-specific, Aug. 17
 by histologic type, Aug. 29
 material of study, Aug. 10-14
 methods of study, Aug. 10-14
 mortality in, Aug. 16-19
 outcome

- with palliative treatment, Aug. 30
- with treatment for cure, Aug. 30
- palpable disorders, prevalence, Aug. 14-15
- papillary, Aug. 27
- physical examination in, Aug. 21-22
- prevalence, Aug. 15-16
- radiotherapy of neck in, Aug. 20
- recurrence, Aug. 32
- results, Aug. 14-44
 - at follow-up, Aug. 37
- statistical methods of study, Aug. 14
- subjects of study, Aug. 10-14
- summary of study, Aug. 44-46
- surgery, Aug. 29-36
 - additional therapy in, Aug. 29-30
 - complications, Aug. 32
 - procedure, and tumor stage and type, Aug. 31
 - for solitary thyroid nodule, Aug. 13-14
- survival in, Aug. 35-44
 - by age, Aug. 42
 - for all patients, Aug. 36-38
 - by histologic type, Aug. 38-39
 - by node status, Aug. 41-42
 - rate, cumulative, Aug. 37
 - by sex, Aug. 43-44
 - time in fatal cases, Aug. 35-36
 - by tumor stage, Aug. 39-40
- symptoms, presenting, Aug. 20-21
- thyroid scan in, Aug. 22-23
- results, Aug. 22
- treatment, Aug. 29-35
 - nonsurgical, Aug. 34-35
- Thyroidal artery, Dec. 39
- Thyroidectomy
 - partial, Aug. 5
 - total, Aug. 4
- Tissue response: to radiation, model of, July 9-14
- Tolbutamide test, Sept. 11-12
- Tomography, computed
 - assisted myelography in medulloblastoma, May 39
- of liposarcoma, Mar. 16
- of medulloblastoma (see Medulloblastoma, CT of)
- in neuroblastoma, Apr. 21
- adrenal, in infant, Apr. 22
- in staging system for medulloblastoma, May 46-48
- of trophoblastic tumor, Dec. 38
- Toxicity
 - of chemotherapy in medulloblastoma, June 23-24
 - of cisplatin, Dec. 38-39
 - nephrotoxicity (see Nephrotoxicity)
- Trauma: vascular, complicating infusion, Nov. 13-15
- Trophoblastic tumor: CT of, Dec. 38
- Trunk: in rhabdomyosarcoma, Apr. 38-39, 40-41
- Tumors
 - bladder, and
 - rhabdomyosarcoma, Apr. 36-38
 - brain (see Brain, tumors)
 - CNS (see Cancer, CNS)
 - extraosseous, Mar. 21
 - giant cell (see Giant cell tumors)
 - head (see Head and neck tumors)
 - leptomeningeal, deposits, CT of, May 35
 - malignant (see Cancer)
 - multiple endocrine (see Multiple endocrine neoplasia syndromes)
 - neck (see Head and neck tumors)
 - pancreas, mixed endocrine, Sept. 26-28
 - pituitary, therapy goals, Feb. 10
 - posterior fossa, symptoms and signs of, May 19-21
 - prostate, and
 - rhabdomyosarcoma, Apr. 36-38
 - tendosynovial cell, Mar. 20-21
 - trophoblastic, CT of, Dec. 38
 - Wilms' (see Wilms' tumor)

U

- Ulcer: duodenal, embolization in, Nov. 22
- University of Padova Experience, June 22-23
- Uremic-hemolytic syndrome: mitomycin C-induced, kidney after, Oct. 19, 20, 21
- Urinary hemorrhage: infusion for control, Nov. 23
- Urine: sarcoma-associated antigens in, evaluation, Mar. 9
- USL of Perugia Experience, June 23
- Uterine artery infusion: in adenocarcinoma of cervix, Dec. 28

V

- Vaginal rhabdomyosarcoma, Apr. 40
- Vein: portal, infusion after hepatic artery occlusion, Nov. 34-35
- Velban: for hepatic artery infusion in breast carcinoma, Nov. 41
- Venography: of pancreatic head, Sept. 16
- Vessels supply
 - in head and neck tumors, Dec. 39-40
 - redistribution for infusion, Nov. 11
 - trauma complicating infusion, Nov. 13-15

- Vinblastine: for hepatic artery infusion in breast carcinoma, Nov. 41
- Vomiting
 - in cerebellar medulloblastoma, May 22
 - after radiation, June 9-10
- Vulva: melanoma, Dec. 32-33
- Vulvovaginal rhabdomyosarcoma, Apr. 40

W

- Wilms' tumor, Apr. 5-18
 - diagnosis, Apr. 5-10
 - future for, Apr. 15-18
 - of kidney, Apr. 9
 - stage I, Apr. 6
 - metastases of
 - treatment, Apr. 13-15
 - in 2-year-old, Apr. 14
 - preoperative evaluation, Apr. 5-10
 - recommendations for, current, Apr. 15-18
 - stage II, intravenous pyelography of, Apr. 8
 - staging, Apr. 10-11
 - clinicopathologic systems, Apr. 11
 - surgery, hemihypertrophy after, Apr. 7
 - treatment, Apr. 11-15
 - bilateral, Apr. 13-15
 - nonoperative, Apr. 15

X

- X-ray (see Radiation)

artery

astoma,

10

2-33

arcoma,

5

, Apr.

urrent,

r. 8

ems,

hy